Total Payments
$836,408
2024 Payments
$93,646
Companies
33
Transactions
1,103
Medicare Patients
197
Medicare Billing
$22,493
Payment Breakdown by Category
Other$466,509 (55.8%)
Consulting$224,266 (26.8%)
Travel$112,336 (13.4%)
Food & Beverage$18,795 (2.2%)
Research$14,065 (1.7%)
Education$437.91 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $466,509 | 221 | 55.8% |
| Consulting Fee | $224,266 | 81 | 26.8% |
| Travel and Lodging | $112,336 | 269 | 13.4% |
| Food and Beverage | $18,795 | 485 | 2.2% |
| Unspecified | $14,065 | 36 | 1.7% |
| Education | $437.91 | 11 | 0.1% |
Payments by Type
General
$822,343
1,067 transactions
Research
$14,065
36 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| United Therapeutics Corporation | $384,014 | 431 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $273,758 | 363 | $0 (2024) |
| Merck Sharp & Dohme LLC | $63,182 | 69 | $0 (2024) |
| Gilead Sciences, Inc. | $38,674 | 80 | $0 (2019) |
| Actelion Pharmaceuticals, Ltd | $37,940 | 36 | $0 (2020) |
| Bayer Healthcare Pharmaceuticals Inc. | $10,039 | 8 | $0 (2023) |
| Mylan Inc. | $7,854 | 10 | $0 (2024) |
| Insmed, Inc. | $4,500 | 1 | $0 (2022) |
| Acceleron Pharma, Inc. | $3,662 | 2 | $0 (2021) |
| Medtronic Vascular, Inc. | $3,281 | 7 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $93,646 | 108 | Actelion Pharmaceuticals US, Inc. ($36,844) |
| 2023 | $90,150 | 157 | United Therapeutics Corporation ($44,367) |
| 2022 | $91,153 | 113 | Actelion Pharmaceuticals US, Inc. ($59,516) |
| 2021 | $66,979 | 70 | United Therapeutics Corporation ($50,738) |
| 2020 | $24,046 | 28 | United Therapeutics Corporation ($16,730) |
| 2019 | $136,879 | 212 | United Therapeutics Corporation ($84,358) |
| 2018 | $139,969 | 190 | Actelion Pharmaceuticals US, Inc. ($59,791) |
| 2017 | $193,587 | 225 | United Therapeutics Corporation ($99,312) |
All Payment Transactions
1,103 individual payment records from CMS Open Payments — Page 1 of 45
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/18/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/18/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/18/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Travel and Lodging | Cash or cash equivalent | $75.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/17/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $26.83 | General |
| Category: Cardiology | ||||||
| 12/11/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $28.68 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/10/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $49.29 | General |
| Category: Rheumatology | ||||||
| 12/08/2024 | Mylan Inc. | REVATIO (Drug) | Travel and Lodging | In-kind items and services | $229.50 | General |
| Category: PAH, PDE-5 Inhibitors | ||||||
| 12/08/2024 | Mylan Inc. | REVATIO (Drug) | Food and Beverage | In-kind items and services | $128.39 | General |
| Category: PAH, PDE-5 Inhibitors | ||||||
| 12/07/2024 | Mylan Inc. | REVATIO (Drug) | Travel and Lodging | In-kind items and services | $235.85 | General |
| Category: PAH, PDE-5 Inhibitors | ||||||
| 12/07/2024 | Mylan Inc. | REVATIO (Drug) | Food and Beverage | In-kind items and services | $192.59 | General |
| Category: PAH, PDE-5 Inhibitors | ||||||
| 12/07/2024 | Mylan Inc. | REVATIO (Drug) | Travel and Lodging | In-kind items and services | $68.53 | General |
| Category: PAH, PDE-5 Inhibitors | ||||||
| 12/06/2024 | Mylan Inc. | REVATIO (Drug) | Travel and Lodging | In-kind items and services | $233.57 | General |
| Category: PAH, PDE-5 Inhibitors | ||||||
| 12/06/2024 | Mylan Inc. | REVATIO (Drug) | Food and Beverage | In-kind items and services | $224.68 | General |
| Category: PAH, PDE-5 Inhibitors | ||||||
| 12/06/2024 | Mylan Inc. | REVATIO (Drug) | Travel and Lodging | In-kind items and services | $96.29 | General |
| Category: PAH, PDE-5 Inhibitors | ||||||
| 12/05/2024 | Mylan Inc. | REVATIO (Drug) | Travel and Lodging | In-kind items and services | $249.62 | General |
| Category: PAH, PDE-5 Inhibitors | ||||||
| 12/04/2024 | Mylan Inc. | REVATIO (Drug) | Travel and Lodging | In-kind items and services | $6,194.83 | General |
| Category: PAH, PDE-5 Inhibitors | ||||||
| 11/26/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $28.29 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 11/25/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $21.99 | General |
| Category: Cardiology | ||||||
| 11/20/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $32.63 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/19/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,050.00 | General |
| Category: Cardiology | ||||||
| 11/19/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Travel and Lodging | Cash or cash equivalent | $25.46 | General |
| Category: Cardiology | ||||||
| 11/19/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $21.82 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/17/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Travel and Lodging | In-kind items and services | $543.40 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/17/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Travel and Lodging | In-kind items and services | $340.07 | General |
| Category: CARDIOVASCULAR | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ADAPT - A PATIENT REGISTRY OF THE REAL-WORLD USE OF ORENITRAM | United Therapeutics Corporation | $3,491 | 15 |
| DelIVery for PAH | Medtronic Vascular, Inc. | $3,281 | 7 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION PH IN HEART FAILURE WITH PRESERVED EJECTION FRACTION HFPEF | United Therapeutics Corporation | $3,250 | 3 |
| A MULTICENTER RANDOMIZED DOUBLE-BLINDED PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INHALED TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION DUE TO PARENCHYMAL LUNG DISEASE | United Therapeutics Corporation | $1,125 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION | United Therapeutics Corporation | $982.50 | 1 |
| AN OPEN-LABEL, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABIL | GlaxoSmithKline, LLC. | $914.77 | 7 |
| STUDY TO COMPARE TRIPLE THERAPY ORAL TREPROSTINIL AMBRISENTAN AND TADALAFIL WITH DUAL THERAPY AMBRISENTAN TADALAFIL AND PLACEBO IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION | United Therapeutics Corporation | $520.00 | 1 |
| QUERI EXTENSION - AC-052428 USA | Actelion Pharmaceuticals US, Inc. | $500.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 37 | 60 | $16,980 | $3,733 |
| 2022 | 2 | 38 | 72 | $21,825 | $5,494 |
| 2021 | 3 | 64 | 98 | $29,110 | $7,603 |
| 2020 | 4 | 58 | 87 | $19,856 | $5,662 |
Total Patients
197
Total Services
317
Medicare Billing
$22,493
Procedure Codes
11
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 17 | 32 | $13,760 | $3,013 | 21.9% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 20 | 28 | $3,220 | $719.28 | 22.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 21 | 43 | $18,490 | $4,685 | 25.3% |
| 94618 | Test for exercise-induced lung stress | Office | 2022 | 17 | 29 | $3,335 | $809.30 | 24.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 24 | 44 | $18,010 | $4,928 | 27.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 17 | 18 | $6,960 | $1,637 | 23.5% |
| 94618 | Test for exercise-induced lung stress | Office | 2021 | 23 | 36 | $4,140 | $1,038 | 25.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 20 | 36 | $11,015 | $3,256 | 29.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 13 | 15 | $4,841 | $968.57 | 20.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 12 | 12 | $1,560 | $779.33 | 50.0% |
| 94618 | Test for exercise-induced lung stress | Office | 2020 | 13 | 24 | $2,440 | $658.16 | 27.0% |
About Dr. Ronald Oudiz, M.D
Dr. Ronald Oudiz, M.D is a Cardiovascular Disease healthcare provider based in Torrance, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1316957228.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ronald Oudiz, M.D has received a total of $836,408 in payments from pharmaceutical and medical device companies, with $93,646 received in 2024. These payments were reported across 1,103 transactions from 33 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($466,509).
As a Medicare-enrolled provider, Oudiz has provided services to 197 Medicare beneficiaries, totaling 317 services with total Medicare billing of $22,493. Data is available for 4 years (2020–2023), covering 11 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Torrance, CA
- Active Since 08/09/2006
- Last Updated 08/19/2021
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1316957228
Products in Payments
- UPTRAVI (Drug) $128,657
- NONE (Drug) $75,830
- ORENITRAM (Drug) $65,120
- REMODULIN (Drug) $62,125
- TYVASO (Drug) $32,064
- WINREVAIR (Biological) $25,858
- OPSUMIT (Drug) $23,972
- Letairis (Drug) $23,075
- OPSUMIT MACITENTAN (Drug) $13,968
- Adempas (Drug) $10,039
- REVATIO (Drug) $7,854
- CardioMEMS HF System (Device) $2,621
- BOSENTAN (Drug) $548.80
- ENTRESTO (Drug) $351.00
- XARELTO (Drug) $334.43
- AFREZZA (Drug) $318.75
- LifeVest (Device) $248.58
- CAMZYOS (Drug) $155.72
- FUROSCIX (Drug) $109.29
- Arcalyst (Drug) $95.25
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Torrance
Matthew Budoff, M.d, M.D
Cardiovascular Disease — Payments: $5.0M
Cardiovascular Disease $5.0M
Dr. Rishi Kaushal, M.d, M.D
Cardiovascular Disease — Payments: $108,970
Cardiovascular Disease $108,970
Dr. Matthew Ostrom, M.d, M.D
Cardiovascular Disease — Payments: $57,874
Cardiovascular Disease $57,874
Joseph Thomas, Md, MD
Cardiovascular Disease — Payments: $52,485
Cardiovascular Disease $52,485
Dr. Leonard Scuderi, M.d, M.D
Cardiovascular Disease — Payments: $42,878
Cardiovascular Disease $42,878
Dr. Jashdeep Dhoot, M.d, M.D
Cardiovascular Disease — Payments: $21,247
Cardiovascular Disease $21,247